Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Comorbidities in Headache Disorders / / edited by Maria Adele Giamberardino, Paolo Martelletti
| Comorbidities in Headache Disorders / / edited by Maria Adele Giamberardino, Paolo Martelletti |
| Edizione | [1st ed. 2017.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2017 |
| Descrizione fisica | 1 online resource (XIII, 217 p. 7 illus., 3 illus. in color.) |
| Disciplina | 616 |
| Collana | Headache |
| Soggetto topico |
Internal medicine
Neurology Pain medicine Rheumatology Psychiatry Otorhinolaryngology Internal Medicine Neurology Pain Medicine |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1 Cardio-cerebrovascular comorbidity -- 2 Psychiatric comorbidity -- 3 Epilepsy comorbidity -- 4 Visceral pain comorbidity -- 5 Fibromyalgia comorbidity -- 6 Sleep disorders comorbidity -- 7 Obesity and other metabolic comorbidities -- 8 Comorbidity in paediatric headaches -- 9 Temporomandibular joint dysfunction comorbidity -- 10 Orofacial Pain comorbidity -- 11 Myofascial trigger points comorbidity -- 12 Neuropathic pain comorbidity. |
| Record Nr. | UNINA-9910148853203321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Handbook of Headache [[electronic resource] ] : Practical Management / / edited by Paolo Martelletti, Timothy J. Steiner
| Handbook of Headache [[electronic resource] ] : Practical Management / / edited by Paolo Martelletti, Timothy J. Steiner |
| Edizione | [1st ed. 2011.] |
| Pubbl/distr/stampa | Milano : , : Springer Milan : , : Imprint : Springer, , 2011 |
| Descrizione fisica | 1 online resource (XXVI, 760p. 26 illus.. eReference.) |
| Disciplina | 616.8491 |
| Collana | Springer reference |
| Soggetto topico |
Medicine
Emergency medicine Internal medicine Neurosciences Medicine/Public Health, general Emergency Medicine Internal Medicine |
| ISBN | 88-470-1700-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction -- Classification and Controversies -- Epidemiology -- Genetics Global Burden Public Health Economy -- Migraine -- Tension Type Headache -- TAC’s -- Headache in Developmental Age -- Neuroimaging -- Comorbidities -- Posttraumatic Headache -- Cervicogenic Headache -- Secondary Headaches -- Medication Overuse Headache -- Acute Therapy -- Headache in Emergency Room -- Preventative Therapy -- Future Drugs -- Invasive Techniques -- "The Multiple" Management -- The Lay Organization Role -- Suggested Links. Acknowledgements. |
| Record Nr. | UNINA-9910483568603321 |
| Milano : , : Springer Milan : , : Imprint : Springer, , 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Migraine in medicine : a machine-generated overview of current research / / edited by Paolo Martelletti
| Migraine in medicine : a machine-generated overview of current research / / edited by Paolo Martelletti |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (1022 pages) |
| Disciplina | 616.84912 |
| Soggetto topico | Migraine |
| ISBN |
9783030973599
9783030973582 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910586579103321 |
| Cham, Switzerland : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Monoclonal Antibodies in headache : from bench to patient / / Antoinette Massen van den Brink, Paolo Martelletti, editors
| Monoclonal Antibodies in headache : from bench to patient / / Antoinette Massen van den Brink, Paolo Martelletti, editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (176 pages) |
| Disciplina | 616.047 |
| Collana | Headache |
| Soggetto topico |
Headache - Treatment
Cefalàlgia Terapèutica |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-69032-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Foreword -- Preface -- Contents -- Chapter 1: The CGRP Family of Neuropeptides and their Receptors in the Trigeminovascular System -- 1.1 Introduction -- 1.2 The Receptors of the CGRP Family -- 1.3 The CGRP Family of Ligands and their Distribution -- 1.4 Relation Between Expression of Ligands and Receptors -- 1.4.1 Ligand Experiments -- 1.4.2 Receptor Expressions -- 1.4.3 Ligand/Receptor Expression -- 1.5 Conclusion -- References -- Chapter 2: Pharmacology -- Where Do the mAbs Act, Gepants Versus mAbs -- 2.1 Pharmacology -- 2.2 Gepants -- 2.3 mAbs Targeting the CGRPergic System -- 2.4 Conclusions -- References -- Chapter 3: Monoclonal Antibody Biology -- 3.1 Introduction -- 3.2 Structural Features of Antibodies -- 3.3 Therapeutic Antibody Types -- 3.4 Monoclonal Antibody Nomenclature -- 3.5 Pharmacodynamics (PD) and Pharmacokinetics (PK) -- 3.5.1 Absorption -- 3.5.2 Distribution -- 3.5.3 Elimination -- 3.6 Safety and Immunogenicity -- 3.7 Conclusion -- References -- Chapter 4: Guidelines for Clinical Trials -- 4.1 Patient Selection -- 4.1.1 Headache Definition -- 4.1.2 Age and Sex -- 4.1.3 Comorbidities and Concomitant Medications -- 4.1.4 Headache Onset and Duration -- 4.1.5 Previous Treatments -- 4.2 Operating Procedures -- 4.2.1 The Issue of Comparison with Placebo -- 4.2.2 Screening and Baseline Phase -- 4.2.3 Trial Duration -- 4.2.4 Open-Label Extensions -- 4.3 Endpoint Assessment -- 4.3.1 Definitions -- 4.3.1.1 Migraine Day -- 4.3.1.2 Headache Day -- 4.3.1.3 Responder Rate -- 4.3.2 Headache-Related Endpoints -- 4.3.3 Assessment Timepoints -- 4.3.4 Acute Medication Use -- 4.3.5 Patient-Reported Outcomes -- 4.3.6 Adverse Events -- 4.4 The Issues of Cluster Headache Trials -- 4.5 Conclusions and Future Perspectives -- References -- Chapter 5: Human Models -- 5.1 Introduction -- 5.2 Evidence of CGRP Involvement in Migraine Induction.
5.3 Mechanisms of CGRP-Induced Migraine Attacks -- 5.4 cAMP and cGMP Molecular Signaling Pathway -- 5.5 CGRP Models for Drug Testing -- 5.6 Future Perspectives and Conclusion -- Glossary -- References -- Chapter 6: CGRP Antibodies for Animal Models of Primary and Secondary Headache Disorders -- 6.1 Introduction -- 6.2 Animal Models of Primary Headaches -- 6.2.1 Animal Models of Migraine -- 6.2.1.1 Peripheral Models -- Nitroglycerin-Induced Model -- Models Induced by Peripheral Injection of CGRP -- Models Induced by Electrical Stimulation of TG -- Models Induced by Activation of Meninges -- Electrical or Mechanical Stimulation of Meninges -- Transient Receptor Potential (TRP) Channel Activation -- Dural Inflammation and Decreased Dural pH -- 6.2.1.2 Central Models -- Models Induced by Central Injection of CGRP -- 6.2.1.3 Other Models -- Models of Cortical Spreading Depression (CSD) -- The Spontaneous Trigeminal Allodynia (STA) Model -- Models Induced by Sleep Deprivation and Stress -- 6.3 Animal Models of Secondary Headaches -- 6.3.1 Post-Traumatic Headache (PTH) -- 6.3.2 Medication Overuse Headache (MOH) -- 6.4 Conclusion and Future Directions -- References -- Chapter 7: Galcanezumab -- 7.1 Therapeutic Indication -- 7.2 Mode of Action -- 7.3 Preclinical Trials -- 7.4 Phase II Clinical Trial Program for the Prevention of Migraine -- 7.5 Phase III Registration Trials for the Prevention of Episodic Migraine -- 7.6 Phase III Registration Trials for the Prevention of Chronic Migraine -- 7.7 CONQUER-A Phase IIIb Clinical Trial in a Difficult-to-Treat Cohort -- 7.8 Functional Improvement with Galcanezumab -- References -- Chapter 8: Eptinezumab -- 8.1 Introduction -- 8.2 Development -- 8.3 Administration -- 8.4 Pharmacokinetics -- 8.5 Pharmacodynamics and Mechanism of Action -- 8.6 Eptinezumab Clinical Trials -- 8.7 Conclusion -- References. Chapter 9: Erenumab -- 9.1 General -- 9.2 Compelling Evidence from Randomized Clinical Trials -- 9.3 Sustained Efficacy and Safety in Open-Label Extension Studies -- 9.4 Difficult-to-Treat Patients -- 9.5 Postmarketing Safety Data -- 9.6 Real-World Clinical Experience -- 9.7 Future Perspectives -- References -- Glossary -- Chapter 10: Fremanezumab -- 10.1 Introduction to the Compound -- 10.2 Chemistry -- 10.3 Fremanezumab Pharmacodynamics and Pharmacokinetics -- 10.4 Fremanezumab Clinical Efficacy -- 10.5 Fremanezumab Safety and Tolerability -- 10.6 Ongoing Trials -- 10.7 Conclusion -- References -- Chapter 11: Potential Side Effects and Pregnancy -- 11.1 Introduction -- 11.2 CGRP and (Patho)Physiology -- 11.2.1 CGRP and Cardiovascular System -- 11.2.2 CGRP, Inflammation, and Wound Healing -- 11.2.3 CGRP and the Gastrointestinal System -- 11.2.4 CGRP and the Central Nervous System -- 11.2.5 CGRP and Other Receptors -- 11.3 CGRP and Pregnancy -- 11.3.1 Pregnancy and CGRP (Receptor)-Antibodies -- 11.4 Conclusion -- References -- Chapter 12: Real-World Data, Clinical Practice So Far -- 12.1 Introduction -- 12.2 Design of the Observational Studies -- 12.2.1 Selection Criteria -- 12.2.1.1 Inclusion Criteria -- 12.2.1.2 Exclusion Criteria and Study Failure -- 12.2.2 Dosage -- 12.2.3 Outcomes of the Studies -- 12.2.3.1 Monthly Migraine, Monthly Headache Days, and Responder Rate -- 12.2.3.2 Monthly Acute Medication Consumption -- 12.2.3.3 Disability, Comorbidities, and Patient-Reported Outcomes -- 12.2.3.4 Assessment Time Points -- 12.3 Patients' Baseline Characteristics -- 12.4 Results -- 12.4.1 Erenumab -- 12.4.1.1 Efficacy -- Monthly Migraine Days and Responder Rate -- Acute Medications Consumption and Medication Overuse -- HIT-6 and Other Scales -- 12.4.1.2 Safety -- 12.4.2 Galcanezumab -- 12.4.2.1 Efficacy -- 12.4.2.2 Safety -- 12.5 Case Reports. 12.6 Limitations -- 12.7 Conclusions and Further Perspectives -- References -- Chapter 13: Migraine Versus Cluster Headache and Potential Other Indications -- 13.1 Introduction -- 13.2 Migraine -- 13.3 Cluster Headache -- 13.4 Persistent Post-Traumatic Headache -- References. |
| Record Nr. | UNINA-9910483537303321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Non-migraine primary headaches in medicine : a machine-generated overview of current research / / edited by Paolo Martelletti
| Non-migraine primary headaches in medicine : a machine-generated overview of current research / / edited by Paolo Martelletti |
| Edizione | [1st ed. 2023.] |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2023] |
| Descrizione fisica | 1 online resource (380 pages) |
| Disciplina | 658 |
| Soggetto topico | Headache |
| ISBN |
9783031208942
9783031208935 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | GLOBAL IMPACT AND POPULATION FORECASTING. Epidemiology -- Global Burden -- ÆTIOLOGY AND MECHANISMS: Genetics.-Pathophysiology.-.DIAGNOSIS AND CLINICAL FEATURES: ICHD-3 Classification.-Clinical Presentation.-Associations/Comorbidities.-MANAGEMENT OF COMPLEXITY: Multimodal Management -- Risk factores and Complications.-Special Settings Treatment.-Lifestyle and Patient Education. |
| Record Nr. | UNINA-9910659489503321 |
| Cham, Switzerland : , : Springer, , [2023] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Novel synthetic drugs in migraine / / Paolo Martelletti and Lars Edvinsson, editors
| Novel synthetic drugs in migraine / / Paolo Martelletti and Lars Edvinsson, editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer Nature Switzerland AG, , [2022] |
| Descrizione fisica | 1 online resource (114 pages) |
| Disciplina | 615.1 |
| Collana | Headache Series |
| Soggetto topico |
Synthetic drugs
Migraine |
| ISBN | 3-030-95334-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910568262803321 |
| Cham, Switzerland : , : Springer Nature Switzerland AG, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||